Drug intelligence / Profile preview

AB003

Development stage: Preclinical
Lead developer: AKSO Biopharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Parenteral, Intravenous

Overview

AB003 is a preclinical-stage fusion protein drug conjugate (FDC) developed by AKSO Biopharmaceutical (also known as AKSO Biotechnology) for the treatment of solid tumors. It consists of a PD-L1/PD-L2-targeting decoy receptor fusion protein conjugated to a hypoxia-activated payload. By targeting both PD-L1 and PD-L2, AB003 is designed to inhibit immune checkpoint pathways while selectively delivering its cytotoxic payload to the hypoxic microenvironment characteristic of solid tumors, thereby minimizing systemic toxicity and enhancing therapeutic efficacy. The candidate is currently in IND-enabling development.

Targets

CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)

Beyond the preview

Go deeper on AB003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB003.